ATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor ...

-- Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokinetics -- SBS-147 is a novel and potent oral analgesic with a differentiated safety profile being developed for acute ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding RNA-based compound designed to provide a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison Aligos anticipates dosing the first subject in Q2 2024 with topline safety and efficacy data expected in Q4 2024 SOUTH ...

SBS-147 is a novel and potent oral analgesic with a differentiated safety profile being developed for acute and chronic pain The phase 1 SAD/MAD and phase 2 clinical study of SBS-147 are supported by ...